US COST-EFFECTIVENESS OF LENACAPAVIR PLUS OPTIMIZED BACKGROUND REGIMEN VERSUS OTHER TREATMENTS FOR MULTI-DRUG RESISTANT HIV

被引：0
|
作者：
Vardanega, V. [1 ]
New, E. [1 ]
Mezzio, D. [2 ]
Eddowes, L. A. [1 ]
机构：
[1] Costello Med, London, England
[2] Gilead Sci, Foster City, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE472
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [31] Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States
    Kit N. Simpson
    Pamela P. Pei
    Jörgen Möller
    Robert W. Baran
    Birgitta Dietz
    William Woodward
    Kristen Migliaccio-Walle
    J. Jaime Caro
    PharmacoEconomics, 2013, 31 : 427 - 444
  • [32] Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States
    Simpson, Kit N.
    Pei, Pamela P.
    Moeller, Joergen
    Baran, Robert W.
    Dietz, Birgitta
    Woodward, William
    Migliaccio-Walle, Kristen
    Caro, J. Jaime
    PHARMACOECONOMICS, 2013, 31 (05) : 427 - 444
  • [33] COST-EFFECTIVENESS OF ADDING BEDAQUILINE TO BACKGROUND DRUG REGIMENS FOR THE TREATMENT OF MULTIDRUG-RESISTANT AND EXTENSIVELY-RESISTANT TUBERCULOSIS IN ITALY
    Codecasa, L. R.
    Toumi, M.
    D'Ausilio, A.
    Aiello, A.
    Da Mele, F.
    Termini, R.
    Uglietti, A.
    Hettle, R.
    Graziano, G.
    De Lorenzo, S.
    VALUE IN HEALTH, 2016, 19 (07) : A553 - A554
  • [34] Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis
    Tiberi, Simon
    Sotgiu, Giovanni
    D'Ambrosio, Lia
    Centis, Rosella
    Arbex, Marcos Abdo
    Arrascue, Edith Alarcon
    Alffenaar, Jan Willem
    Caminero, Jose A.
    Gaga, Mina
    Gualano, Gina
    Skrahina, Alena
    Solovic, Ivan
    Sulis, Giorgia
    Tadolini, Marina
    Guizado, Valentina Alarcon
    De Lorenzo, Saverio
    Arias, Aurora Jazmin Roby
    Scardigli, Anna
    Akkerman, Onno W.
    Aleksa, Alena
    Artsukevich, Janina
    Avchinko, Vera
    Bonini, Eduardo Henrique
    Marin, Felix Antonio Chong
    Lopez, Lorena Collahuazo
    de Vries, Gerard
    Dore, Simone
    Kunst, Heinke
    Matteelli, Alberto
    Moschos, Charalampos
    Palmieri, Fabrizio
    Papavasileiou, Apostolos
    Payen, Marie-Christine
    Piana, Andrea
    Spanevello, Antonio
    Vasquez, Dante Vargas
    Viggiani, Pietro
    White, Veronica
    Zumla, Alimuddin
    Migliori, Giovanni Battista
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (09) : 1188 - +
  • [35] Cost-effectiveness and cost-utility analysis of Haemate-P versus other von Willebrand disease treatments in Spain
    Megias-Vericat, Juan E.
    Escolar, Gines
    Wilson, Michele R.
    Mendez, Pablo
    Mcdade, Cheryl L.
    Barrientos, Laura Vidal
    Tomic, Radovan
    Panebianco, Marco
    Linden, Stephan
    Yan, Songkai
    JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01)
  • [36] Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan
    Yanagi, Yasuo
    Fukuda, Aya
    Barzey, Victor
    Adachi, Kenji
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) : 204 - 212
  • [37] Cost-effectiveness of pretomanid-based regimen for highly drug-resistant TB in a low-burden setting
    Fekadu, G.
    Wang, Y.
    You, J. H. S.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2024, 28 (02) : 81 - 85
  • [38] Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy
    Mikula, James M.
    Manion, Maura M.
    Maldarelli, Frank
    Suarez, Lucila M.
    Norman-Wheeler, Jaha F.
    Ober, Alex G.
    Dewar, Robin L.
    Kopp, Jeffrey B.
    Lane, H. Clifford
    Pau, Alice K.
    ANTIVIRAL THERAPY, 2016, 21 (06) : 553 - 558
  • [39] A US PAYER COST-EFFECTIVENESS ANALYSIS OF IMIPENEM/CILASTATIN/RELEBACTAM VERSUS COLISTIN PLUS IMIPENEM/CILASTATIN IN PATIENTS WITH CARBAPENEM-RESISTANT BACTERIAL INFECTIONS
    Naik, J.
    Ralph, L.
    Massello, M.
    Dillon, R.
    Mccann, E.
    Yang, J.
    VALUE IN HEALTH, 2021, 24 : S110 - S110
  • [40] Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis
    Ye D.
    Liang X.
    Chen X.
    Li Y.
    Scientific Reports, 14 (1)
12345